Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
InflaRx (IFRX) Stock Pops as FDA Grants Emergency Use Authorization
10:06am, Wednesday, 05'th Apr 2023
InflaRx (NASDAQ: IFRX ) stock is getting a boost on Wednesday following an update from the FDA concerning its Covid-19 treatment. The big news investors are celebrating today is vilobelimab getting Em
InflaRx: On Watch For A Buy During Tax Loss Selling Season
02:34am, Wednesday, 14'th Dec 2022
IFRX has been beaten down much like many other biotech companies. The company has a lead drug which is being considered for EUA in the US and use in the EU for critical covid.
InflaRx to Present at Upcoming Scientific and Investor Conferences
07:30am, Friday, 09'th Sep 2022
JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,
Here's Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy
01:33pm, Wednesday, 17'th Aug 2022
Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors?
InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Thursday, 11'th Aug 2022
InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch
11:30am, Thursday, 28'th Jul 2022
Biotech penny stocks to watch this week. The post Best Penny Stocks To Buy As Recession Begins?
Why Is InflaRx (IFRX) Stock Up 40% Today?
03:12pm, Tuesday, 26'th Jul 2022
InflaRx (NASDAQ: IFRX ), a maker of anti-inflammatory therapeutics, is up 40% today after announcing it's pursuing emergency-use authorization from the U.S. Food and Drug Administration for its Covid-
InflaRx Provides Development Update For Vilobelimab In Skin Disorder, COVID-19
12:09pm, Wednesday, 29'th Jun 2022
InflaRx N.V. (NASDAQ: IFRX) provided a development update for its monoclonal anti-C5a antibody, vilobelimab, in pyoderma gangrenosum (PG) and severe COVID-19.
InflaRx to Present at the H.C. Wainwright Global Investment Conference
07:30am, Tuesday, 17'th May 2022
JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, to
InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients
01:33pm, Thursday, 31'st Mar 2022
InflaRx N.V. (NASDAQ: IFRX) announced topline data from Phase 3 part of Phase 2/3 PANAMO study of vilobelimab in critically ill COVID-19 patients.
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
10:32am, Thursday, 24'th Mar 2022
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021.
FDA Issues Corrected Advice To InflaRx's Vilobelimab Study In Skin Disease
10:16am, Thursday, 17'th Mar 2022
InflaRx N.V. (NASDAQ: IFRX) has received a corrected advice letter from the FDA regarding its Phase 3 vilobelimab program for hidradenitis suppurativa (HS).
InflaRx to Present at Annual SVB Leerink Global Health Conference
07:30am, Tuesday, 08'th Feb 2022
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, w
InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder
03:39pm, Monday, 15'th Nov 2021
InflaRx N.V. (NASDAQ: IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV).
InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference
07:30am, Thursday, 11'th Nov 2021
JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announ
